AparnaBio was founded in 2007 to develop targeted nanoparticles for in vivo research and clinical therapeutics. AparnaBio has secured intellectual property protection for its platform technology, established laboratories, expanded its staff, and been awarded significant competitive grant funding.

AparnaBio is advancing its proprietary NanoElectroPlexTM platform, expanding its research and therapeutic applications, and encourages collaborations and partnerships with academia and industry.